Evaluation of Hepatitis B vaccine Immunogenicity in Relation to ABO and Rhesus Blood Group in vaccinated subjects in Bauchi State, Nigeria
DOI:
https://doi.org/10.47430/ujmr.2162.020Keywords:
ABO;, Hepatitis B Virus;, Rhesus blood group;, Vaccine Immunogenicity.Abstract
Hepatitis B virus infection is a global public health issue. It can result in hepatocellular carcinoma (HCC), and liver cirrhosis when not properly managed. The discovery of Hepatitis B vaccine and its incorporation into immunization programmes has brought a drastic decline in the incidence of both chronic and acute hepatitis B. However, this achievement is being confronted by cases of vaccine sub-optimal immune response, non-responsiveness and breakthrough infection which may be associated with the host’s genetic predisposition such as; ABO/Rhesus blood groups and hemoglobin genotype. The study aimed at investigating hepatitis B vaccines responsiveness (immunogenicity) and its association with the hosts’ ABO and Rhesus blood group among vaccinated subjects in Bauchi State Nigeria. This was a cross-sectional investigation comprising of 352 subjects of both sexes from age 1 year to 60 years. Out of the 352 subjects, 196 were vaccinated while 156 were unvaccinated. 5mL of blood samples were collected and analyzed for determination of both ABO and Rhesus blood group while the plasma part of the samples was tested for anti-HBs antibodies by enzyme linked immunosorbent assay (ELISA). The results revealed that 96(49.0%) of the vaccinated subjects had anti-HBs level ≥ 10 IU/L, 65(33.2%) had ≤ 10 IU/L and 35(17.9%) were non-responders while 26(16.7%) of the unvaccinated subjects had anti-HBs level ≥ 10 IU/L (P = 0.003). On the relationship between the ABO/Rhesus group and vaccine immunogenicity, blood group AB had 100% sub-optimal response while group B had 34.2% suboptimal response and 21% non-responders. Blood group A and O had the highest ≥ 10 IU/L anti-HBs protective level of 52.8% and 50.0% respectively. However, there was no significant association between HBV vaccine responsiveness and hosts’ ABO/Rhesus. The protective rate against HBV infection was moderate. Nevertheless, some blood types had higher responses than others. Therefore, a considerable proportion of vaccinated persons should be considered for either booster doses or revaccination.
Downloads
References
Abegaz, S.B. (2021). Human ABO Blood Groups and Their Associations with DifferentDiseases. BioMed Research International Volume, 66(4) 41-50.
https://doi.org/10.1155/2021/6629060
Adebola, T., O., Akin, O., Muhammad, S., Balogun, A., A., Patrick, N., Moses, A.,Abiodun, E. O., Simeon, W. A., Samuel, S., Bolanle, O. P., Musa, S. and Abdulsalami, N. (2016).Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey. AmericanJournal of Tropical Medical Hygiene, 95(4), 902-907.
https://doi.org/10.4269/ajtmh.15-0874
Bauchi Local Government Area. (2018). House to house immunization record. National Programme on Immunization, 12-34.
Berinyuy, B. E., Alawode R Adenike, Mohammed Alkali Bala, Babalola B Shukurat, et al. (2019). Prevalence of Hepatitis B Virus in Nigeria: Review Update. Annal Pub Health and Epidemiology, 1(1), 1-7.
Blumberg BS. (1977). Australia antigen and the biology of hepatitis B. Science, 19(7), 17-25.
https://doi.org/10.1126/science.325649
Casanova, JL. (2015). Human genetic basis of inter-individual variability in the course ofinfection. National Academy of Sciences, 112(51); 127-138.
https://doi.org/10.1073/pnas.1521644112
Cooling, L. (2015). Blood groups in infection and host susceptibility. Clin. Microbiol Review,2(8), 801-870..
https://doi.org/10.1128/CMR.00109-14
Damulak, OD., Ogbenna V., Ma'an O., Rufai SD., Kut T., Bodund A. (2013). Hepatitis B virus sero-positivity among voluntary blood donors at a centralized blood service centre in Nigeria. International Journal of Medical and Applied Sciences 2(3), 10-18.
Fan, Q, Zhang, W, Li, B, Li, D-J, Zhang, J and Zhao, F. (2020). Association Between ABOBlood Group System and COVID-19 Susceptibility in Wuhan. Front. Cell. Infect.Microbiol.10:404.
https://doi.org/10.3389/fcimb.2020.00404
Fuad, AAA.,Naila, AA., Fawzi, A., Nader., SA., Mohammed SA., Tari, G., BH and Atif AE,(2017).Assessment of Immunization to Hepatitis Vaccine among Children under Five Years in Rural Areas of Taiz, Yemen Hepatitis Research and Treatment, 21(3), 1-37.
https://doi.org/10.1155/2017/2131627
Expanded programme on immunization (1992). Global Advisory Group Part I. Weekly Epidemiol Rec., 67: 11-5.
Graber-Stiehi, I, (2018).The silent epidemic killing more people than HIV, malaria, TB.Nature and Science, 564(734), 24-7.
https://doi.org/10.1038/d41586-018-07592-7
Gunasekaran, J and Sree, PN, (2018).Prevalence of Non-Responsiveness to an Indigenous Recombinant Hepatitis B Vaccine: A Study among Health Care Workers in a Tertiary Hospital.International Journal for Modern Trends in Science and Technology, 7(6), 10- 16.
Huang, YH, Hsiao LT, Hong YC, et al. (2013). Randomized controlled trial of entecavir prophylaxis for rituximab associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncology, 31(22):2765-72.
https://doi.org/10.1200/JCO.2012.48.5938
James, A. N., Obinna ON, Georgebest ON, Echeonwu SAJ, Onyeka, A., et al. (2012). Studies on Prevalence and Risk Factors for Hepatitis B Surface Antigen among Secondary School Students in North-central, Nigeria. Sierra Leone Journal of Biomedical Research, 3(3): 163-168.
Kim, JH, Kim, YD, Lee, M, et al. (2018). Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatology, 69(5):1066-1073.
https://doi.org/10.1016/j.jhep.2018.07.018
Magaji, F.A., Okolo, M.O., Yiltok, E.S., Golt, W., Anzaku, S.A., Ogwuche, J.,Pam, V.C., Ocheke, A.N., Musa, J., Isichie, C., Imade, G.E., Mutihir, J.T., Ugwu, B.T., Agbaji, O., Sagay, S.A., Zoakanh, A.I and Chn, S.E. (2021). Prevalence of Hepatitis B virus Infection in Pregnant Women with and Without HIV in Jos, Nigeria. International Journal of Infectious Diseases, 10(4): 276-281.
https://doi.org/10.1016/j.ijid.2020.12.058
Mei Sun, Chengyue, Li., Dan, Wu, Pingping, Li Jun Lu, Ying Wang Fengshui Chang,, Xiaohong Li, and, Mo, H. (2018). Impact Evaluation of the Routine Hepatitis B Vaccination Program of Infants in China. Journal of Public Health, 41(1); 158-163.
https://doi.org/10.1093/pubmed/fdy015
National Population Commission. (2006). Nigeria National Population Census. Federal Ministry of Information and Culture Data Population, 23.
Qin, Y and Liao, P. (2018). Hepatitis B virus vaccine breakthrough infection: surveillance of Sgene mutants of HBV. Actavirologica, 6(2), 115-121.
https://doi.org/10.4149/av_2018_210
Olumuyiwa, O. Odusanya Ewan Alufohai, Francois, P. Meurice and Vincent, I.A. (2011). Five year Post Vaccination Efficacy of Hepatitis B Vaccine in rural Nigeria. Human Vaccines, 7(6), 625-629.
https://doi.org/10.4161/hv.7.6.14990
Perrillo, RP, Gish, R., Falck-Ytter, YT. (2015). American Gastroenterological AssociationInstitute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology, 148(1), 221-244.
https://doi.org/10.1053/j.gastro.2014.10.038
Sadoh, AE and Ofili, A. (2014).Hepatitis B infection among Nigerian children admitted to a children's emergency room. African Health sciences, 1(4), 377-385.
https://doi.org/10.4314/ahs.v14i2.13
Szmuness, W., Stevens, CE.,Zang, EA., Harley, EJ and Kellner, A.A. (2018). Controlled Clinical Trial of the Efficacy of the Hepatitis B vaccine (Heptavax B): A final report. Hepatology, 1, 377-385.
https://doi.org/10.1002/hep.1840010502
Wang, De-Shen, Chen, DL.,Ren, C., Wang, Zhi-Qiang Wang, Miao-Zhen Qiu, MZ., Luo, HY., Dong-Sheng Zhang, Feng-Hua Wang, Li, YH and Xu, RH. (2012). ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. International Journal of Cancer,131, 461-468.
https://doi.org/10.1002/ijc.26376
Welker, MW.,Zeuzem, S. (2016). Pre- and post-transplant antiviral therapy (HBV, HCV). Visc Med. 32(2), 105- 109.
https://doi.org/10.1159/000445152
Wiedermann, U., Garner-Spitzer, E and Wagner, A. (2016). Primary Vaccine Failure to Routine Vaccines: Why and what to do? Human Vaccine and Immunotherapeutic, 12(1), 239-243.
https://doi.org/10.1080/21645515.2015.1093263
World Health Organization. (2016). WHO Global health sector strategy on viral hepatitis 20162021: towards ending viral hepatitis. Geneva: Available at:apps.who.int/iris/bitstream/10665/246177/1/WHO HIV 2016.06-eng.pdf. (Last accessed 25 February 2017.
World Health Organization. (2017). Hepatitis B fact sheets no 204. Available at:http://www.who.int/mediacentre/factsheets/fs204/en Accessed 16th January 2012.
Xu, W., Yu, J., Wong, VW. (2017). Mechanism and prediction of HCC development in HBV infection. Best Pract Res Clin Gastroenterology, 31(3), 291-298.
https://doi.org/10.1016/j.bpg.2017.04.011
Yang, L., Liu, F., Tong, X., Hoffmann, D., Zuo, J & Lu, M. (2019). Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infect. Dis. 5, 713-724.
https://doi.org/10.1021/acsinfecdis.8b00337
Zenebe, Y, Muku, W, Yimer MM, Abera B, (2014). Seroprevalence and risk factors of hepatitis B virus and human immunodeficiency virus infection among pregnant women in Bahir Dar city, Northern Ethiopia: a cross sectional study. Infectious Diseases, 14: 118.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 UMYU Journal of Microbiology Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
